Clearmind Medicine Inc (CMND) FinancialsCMNDClearmind Medicine Inc

Evaluating the bottom line, Clearmind Medicine Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -106.98%, provide a clear picture of how effectively CMND converts its operational activities into shareholder value.

In the context of the broader market, CMND competes directly with industry leaders such as AQMS and RETO. With a market capitalization of $2.83M, it holds a significant position in the sector. When comparing efficiency, CMND's gross margin of N/A stands against AQMS's N/A and RETO's 43.26%. Such benchmarking helps identify whether Clearmind Medicine Inc is trading at a premium or discount relative to its financial performance.

Clearmind Medicine Inc. has shown consistent financial losses, with a net income of -$3,854,583 in Q1 2026 and a gross profit of -$14,218 in Q3 2026. The company has a current ratio of 4.31, indicating good short-term liquidity, but this does not offset the ongoing losses.